Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03945318 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
A Phase 1 study of IgA Nephropathy, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 16
- Study locations
NCT03945318 is a Phase 1 study of IgA Nephropathy that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 103 participants, below the 157-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (34% lower). The trial reports 16 study locations across 10 states.
The verdict
NCT03945318, a Phase 1 study of IgA Nephropathy, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 16
- Study locations
Study Summary
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).
Conditions Studied
Interventions
- DRUG BION-1301 Single Dose
- DRUG Placebo Single Dose
- DRUG BION-1301 Multiple Doses
- DRUG Placebo Multiple Doses
Study Locations (16)
Gyeonggi-do
- Hallym University Sacred Heart Hospital - Anyang-si
- National Health Insurance Service Ilsan Hospital - Goyang-si
- Hanyang University Guri Hostpital - Guri-si
- Seoul National University Bundang Hospital - Seongnam-si
Texas
- Liberty Research Center - Arlington
- Liberty Research Center - Dallas
- Prolato Clinical Research Center - Houston
Florida
- Nephrology Associates of Central Florida - Orlando
- Elixia Tampa, LLC - Tampa
California
- Amicis Research Center - Northridge
Colorado
- Colorado Kidney Care, P.C. - Denver
New York
- New York Nephrology - Clifton Park
Oklahoma
- Chris Sholer, P.C. - Oklahoma City
Chungcheongnam-do
- Soon Chun Hyang University Hospital Cheonan - Cheonan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-04-08 |
| Est. Completion | 2026-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03945318
The ClinicalTrials.gov registry entry for NCT03945318 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 157-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (34% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IgA Nephropathy appearing as the primary indexed condition, and to 4 interventions - of which BION-1301 Single Dose is the first listed.
NCT03945318 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Gyeonggi-do, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT03945318 about?
NCT03945318 is a clinical study titled "Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)". Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).
What is the current status of trial NCT03945318?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2019-04-08. Estimated completion is 2026-04-13.
What conditions does trial NCT03945318 study?
This clinical trial studies the following conditions: IgA Nephropathy.
What interventions are being tested in trial NCT03945318?
The interventions under investigation include: BION-1301 Single Dose (DRUG), Placebo Single Dose (DRUG), BION-1301 Multiple Doses (DRUG), Placebo Multiple Doses (DRUG).
Who is sponsoring clinical trial NCT03945318?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03945318 being conducted?
This trial has 16 study locations across California, Colorado, Florida, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of BHV-1400 in IgA Nephropathy
RECRUITING · Phase 1
-
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
RECRUITING · Phase 2
-
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
RECRUITING · Phase 4
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.